Transcat, Inc. (NASDAQ:TRNS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Transcat, Inc. (NASDAQ:TRNS) have been given an average recommendation of “Moderate Buy” by the five research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $105.3333.

TRNS has been the topic of several research analyst reports. Wall Street Zen lowered Transcat from a “hold” rating to a “sell” rating in a research note on Saturday. Zacks Research upgraded Transcat from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Weiss Ratings upgraded Transcat from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, May 28th.

Institutional Trading of Transcat

Several institutional investors and hedge funds have recently bought and sold shares of TRNS. Wellington Management Group LLP raised its stake in Transcat by 677.7% in the fourth quarter. Wellington Management Group LLP now owns 248,539 shares of the scientific and technical instruments company’s stock valued at $14,100,000 after buying an additional 216,579 shares during the period. First Eagle Investment Management LLC bought a new stake in Transcat in the fourth quarter valued at approximately $7,259,000. King Luther Capital Management Corp raised its stake in Transcat by 182.3% in the fourth quarter. King Luther Capital Management Corp now owns 103,750 shares of the scientific and technical instruments company’s stock valued at $5,886,000 after buying an additional 67,000 shares during the period. Royce & Associates LP raised its stake in Transcat by 15.3% in the fourth quarter. Royce & Associates LP now owns 390,546 shares of the scientific and technical instruments company’s stock valued at $22,156,000 after buying an additional 51,774 shares during the period. Finally, Renaissance Technologies LLC raised its stake in Transcat by 109.7% in the fourth quarter. Renaissance Technologies LLC now owns 95,200 shares of the scientific and technical instruments company’s stock valued at $5,401,000 after buying an additional 49,800 shares during the period. Institutional investors own 98.34% of the company’s stock.

Transcat Stock Performance

TRNS opened at $92.88 on Friday. Transcat has a 52-week low of $50.23 and a 52-week high of $94.76. The firm has a market capitalization of $867.59 million, a PE ratio of 160.14 and a beta of 0.71. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.99 and a current ratio of 2.33. The business’s 50-day simple moving average is $81.27 and its 200 day simple moving average is $72.14.

Transcat (NASDAQ:TRNS) last released its quarterly earnings data on Tuesday, May 26th. The scientific and technical instruments company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.05. The firm had revenue of $89.33 million for the quarter, compared to analyst estimates of $89.79 million. Transcat had a return on equity of 5.84% and a net margin of 1.62%. As a group, sell-side analysts expect that Transcat will post 1.71 earnings per share for the current fiscal year.

About Transcat

Transcat, Inc (NASDAQ: TRNS) is a leading provider of calibration, laboratory, and metrology services in North America. Founded in 1964 and headquartered in Ronkonkoma, New York, the company specializes in ensuring the accuracy and compliance of measurement instruments across a wide range of industries. Transcat operates a network of ISO/IEC 17025–accredited laboratories and offers on-site field calibration, instrument repair, and preventive maintenance services.

In addition to its calibration services, Transcat distributes precision instrumentation and related software solutions from top manufacturers.